Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper
Antongiulio Faggiano, Rossella Mazzilli, Annalisa Natalicchio, Valerio Adinolfi, Antonella Argentiero, Romano Danesi, Stella D’Oronzo, Stefano Fogli, Marco Gallo, Dario Giuffrida, Stefania Gori, Monica Montagnani, Alberto Ragni, Valerio Renzelli, Antonio Russo, Nicola Silvestris, Tindara Franchina, Enzo Tuveri, Saverio Cinieri, Annamaria Colao, Francesco Giorgino, Maria Chiara Zatelli
Abstract
Corticosteroids (CSs) are widely used in oncology, presenting several different indications. They are useful for induction of apoptosis in hematological neoplasms, for management of anaphylaxis and cytokine release/hypersensitivity reaction and for the symptomatic treatment of many tumour- and treatment-related complications. If the employment of CSs in the oncological setting results in several benefits for patients and satisfaction for clinicians, on the other hand, many potential adverse events (AEs), both during treatment and after withdrawal of CSs, as well as the duality of the effects of these compounds in oncology, recommend being cautious in clinical practice. To date, several gray zones remain about indications, contraindications, dose, and duration of treatment. In this article, a panel of experts provides a critical review on CSs therapy in oncology, focusing on mechanisms of action and pharmacological characteristics, current and emerging therapeutic indications/contraindications, AEs related to CSs treatment, and the impact on patient outcome.